Method for targeting and killing prostate tumor cells by oncolytic I type herpes simplex viruses
A technology for herpes simplex and prostate cancer, applied in the field of recombinant viruses, can solve problems such as reducing virus replication efficiency, and achieve the effects of improving oncolytic effect, reducing risk, and improving target specificity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0022] experimental method
[0023] HSV-1 Nucleic Acid Extraction Take wild-type HSV-1 virus F strain (purchased from Gibco Company and stored in our laboratory, its complete genome sequence and specific gene structure are shown in NCBI, its NCBI serial number is NC_001806) under the condition of MOI=1 Infect cultured Vero cells. After 24-36 hours, when most of the cells showed cytopathic changes (CPE), the cells were collected and transferred to a 15ml centrifuge tube to remove the cell culture medium by centrifugation. Add 0.3ml of cell lysate (including: 100Mm NaCl, 10Mm Tris.HCl pH8.25Mm EDTA pH8 and 0.5% SDS) to lyse the infected cells and treat with RNaseA (10mg / ml) at 65°C for 1 hour. The above lysate was first treated with an equal volume of Phenol was then extracted with an equal volume of phenol / chloroform (1:1) mixture, the DNA-containing aqueous solution was transferred to a new centrifuge tube, and 1 / 2 volume of 7.5M ammonium acetate and 2 volumes of anhydrous al...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 